Johnson & Johnson logo

Johnson & Johnson (0R34)

Market Closed
12 Dec, 15:30
$
211. 09
+1.68
+0.8%
$
- Market Cap
29.06 P/E Ratio
4.96% Div Yield
4,148 Volume
9.91 Eps
$ 209.41
Previous Close
Day Range
209.61 211.39
Year Range
140.68 211.39
Want to track 0R34 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 38 days

Summary

0R34 closed yesterday higher at $211.09, an increase of 0.8% from Thursday's close, completing a monthly increase of 11.25% or $21.34. Over the past 12 months, 0R34 stock gained 44.82%.
0R34 pays dividends to its shareholders, with the most recent payment made on Dec 09, 2025. The next estimated payment will be in In 2 months on Mar 09, 2026 for a total of $1.3.
The last earnings report, released on Oct 14, 2025, exceeded the consensus estimates by 0.04%. On average, the company has surpassed earnings expectations by 0.04%, based on the last three reports. The next scheduled earnings report is due on Jan 21, 2026.
Johnson & Johnson has completed 6 stock splits, with the recent split occurring on Jun 13, 2001.
The company's stock is traded on 19 different exchanges and in various currencies, with the primary listing on NYSE (USD).

0R34 Chart

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

Reuters | 1 day ago
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.

Seekingalpha | 2 days ago
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.

Zacks | 2 days ago

Johnson & Johnson (0R34) FAQ

What is the stock price today?

The current price is $211.09.

On which exchange is it traded?

Johnson & Johnson is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0R34.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.96%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 2.53.

When is the next earnings date?

The next earnings report will release on Jan 21, 2026.

Has Johnson & Johnson ever had a stock split?

Johnson & Johnson had 6 splits and the recent split was on Jun 13, 2001.

Johnson & Johnson Profile

Media Industry
Communication Services Sector
Joaquin Duato CEO
LSE Exchange
US4781601046 ISIN
US Country
138,100 Employees
25 Nov 2025 Last Dividend
13 Jun 2001 Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400